A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
What is the purpose of this trial?
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
- Trial withEli Lilly and Company
- Start Date11/29/2018
- End Date12/01/2019
- Last Updated05/06/2019
- Study HIC#2000022550